Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC By Ogkologos - July 14, 2025 660 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the IMforte study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Indications for Selpercatinib Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up Safety and Antitumour Activity of Setidegrasib in Patients with Previously Treated Advanced KRAS p.G12D-mutated NSCLC and PADC MOST POPULAR Dad Is Making Baby Giggle, But When He Makes A Sheep... May 21, 2019 EMA Recommends Extension of Indications for Osimertinib December 18, 2024 Safety and Preliminary Signs of Activity of OMO-103, a MYC Inhibitor,... February 9, 2024 FDA Approves Pembrolizumab and Berahyaluronidase alfa-pmph for Subcutaneous Injection October 2, 2025 Load more HOT NEWS “Selfless and Incredible” Mother Leaves Behind Five Children After Battling Breast... A Deep-Learning Model Predicts the Primary System Origin of Malignant Cells... 35-Year-Old Mom Has Been Living With Stage IV Breast Cancer For... EMA Adopts a Positive Opinion for Dabrafenib for the Treatment of...
